BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

EnteroMedics (ETRMD) Announces Maestro(R) RC System Updated Weight Loss Data to Be Presented at the American Society for Metabolic & Bariatric Surgery Annual Meeting


6/14/2011 8:35:16 AM

ST. PAUL, MN--(Marketwire - June 14, 2011) - EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that updated weight loss data from clinical studies of the Company's VBLOC® vagal blocking therapy delivered via the Maestro® Rechargeable (RC) System will be presented at the 28th Annual Meeting of the American Society of Metabolic and Bariatric Surgeons (ASMBS), being held June 13-17 in Orlando, FL. The presentation, titled "Vagal Blocking for the Treatment of Obesity Delivered Using the Fully Implantable Maestro Rechargeable System: 12 Month Results," will be delivered by Dr. Lillian Kow, BMBS, PhD, FRACS, on June 17, 2011 at 8:30 AM ET.

Dr. Kow stated: "The Maestro System is the only surgical intervention to demonstrate a prolonged effect on weight loss and obesity related co-morbidities without compromises in safety, lifestyle or anatomy. The data presented at ASMBS support our increasingly well-established understanding of how VBLOC Therapy affects the underlying physiology of obesity and undermines the feelings of hunger or lack of fullness that sustain it. I look forward to longer-term follow up in the DM2 study and to results of the ongoing, larger outcome ReCharge study."

The Company also announced long-term, updated obesity, diabetes and hypertension clinical results, including weight loss, HbA1c and blood pressure data, from its VBLOC-DM2 ENABLE and EMPOWER Studies of the Maestro® System. For all studies of the Maestro® Systems, there remain no reported therapy-related serious adverse events.

Mark B. Knudson, PhD, EnteroMedics' President and Chief Executive Officer, said: "We continue to see clinically meaningful and durable weight loss results, an excellent overall safety profile, significant effects on the co-morbidities of hypertension and diabetes and high levels of patient acceptance with the Maestro System. These outcomes, which come from a broad patient population, support our confidence in the ongoing pivotal ReCharge Trial, which remains on track for completion of enrollment by year-end. We also continue to make progress in our commercial development efforts for the Maestro System in Australia and select European markets."

Updated Maestro® Rechargeable System Data Presented at ASMBS

Updated data presented at ASMBS included combined excess weight loss (EWL) data from two studies of EnteroMedics' second-generation Maestro® RC System: the Company's initial feasibility study in patients with morbid obesity and the VBLOC-DM2 ENABLE study in patients with morbid obesity and Type-2 diabetes mellitus.

  • Percent excess weight loss (% EWL) (BMI Method from implant, Company presented data):

                       ------------------------------
                       Visit             %EWL     N  
                       ------------------------------
                       4 Weeks           -12.3    33 
                       ------------------------------
                       12 Weeks          -19.9    30 
                       ------------------------------
                       6 Months          -23.5    30 
                       ------------------------------
                       12 Months         -25.4    30 
                       ------------------------------

Updated VBLOC-DM2 ENABLE Study Data

  • Percent excess weight loss (% EWL) (BMI Method from implant, Company updated data):

----------------------------------------------------------------------------
                                                 %EWL                       
Visit (post-device activation)  ( > 12 hours therapy delivery per day)   N  
----------------------------------------------------------------------------
Week 1                                           -9.5                   25  
----------------------------------------------------------------------------
3 Months                                         -20.8                  26  
----------------------------------------------------------------------------
6 Months                                         -25.2                  24  
----------------------------------------------------------------------------
12 Months                                        -27.2                  24  
----------------------------------------------------------------------------
18 Months                                        -24.6                  22  
----------------------------------------------------------------------------
% EWL for all patients (N=24) is -22.6 at 18 Months. Two patients are not   
currently receiving therapy for unrelated medical reasons.                  
Interim analysis. N is patients who have reached those time points and were 
seen for the scheduled visit.                                               

  • HbA1c change in percentage points (Company updated data):

----------------------------------------------------------------------------
Visit (post-device activation)   % HbA1c change         N            P=     
----------------------------------------------------------------------------
Week 1 (Baseline 7.8%)                -0.3              28         0.002    
----------------------------------------------------------------------------
Week 4 (Baseline 7.8%)                -0.7              28        < 0.001   
----------------------------------------------------------------------------
3 Months (Baseline 7.7%)              -0.9              26        < 0.001   
----------------------------------------------------------------------------
12 Months (Baseline 7.7%)             -1.0              26        < 0.001   
----------------------------------------------------------------------------
18 Months (Baseline 8.1%)             -1.2              13        < 0.001   
----------------------------------------------------------------------------

  • Fasting Plasma Glucose Change (Baseline 151.4 mg/dl average)(Company updated data):

----------------------------------------------------------------------------
                                 Glucose Change                             
Visit (post-device activation)       (mg/dl)            N            P=     
----------------------------------------------------------------------------
Week 1                                -20.9             28        < 0.001   
----------------------------------------------------------------------------
6 Months                              -28.7             25         0.002    
----------------------------------------------------------------------------
12 Months                             -27.6             25         0.003    
----------------------------------------------------------------------------
18 Months                             -38.4             12         0.008    
----------------------------------------------------------------------------

  • Change in mean arterial pressure (MAP) in hypertensive patients (baseline 99.5 mmHg, Company updated data):

----------------------------------------------------------------------------
Visit (post-device activation)  MAP change (mmHg)       N            P=     
----------------------------------------------------------------------------
Week 1                                -6.8              15          0.04    
----------------------------------------------------------------------------
6 Months                              -12.5             13        < 0.001   
----------------------------------------------------------------------------
12 Months                             -7.8              14          0.03    
----------------------------------------------------------------------------
18 Months                             -13.0             13         0.002    
----------------------------------------------------------------------------

  • Change in diastolic blood pressure (DBP) in hypertensive patients (baseline 87.2 mmHg, Company updated data):

----------------------------------------------------------------------------
Visit (post-device activation)  DBP change (mmHg)       N            P=     
----------------------------------------------------------------------------
Week 1                                -10.1             12        < 0.001   
----------------------------------------------------------------------------
6 Months                              -13.8             10        < 0.001   
----------------------------------------------------------------------------
12 Months                             -10.2             11         0.009    
----------------------------------------------------------------------------
18 Months                             -15.9             10        < 0.001   
----------------------------------------------------------------------------

Updated EMPOWER Study Results

The EMPOWER study is a randomized, double-blind, controlled pivotal study designed to evaluate the safety and efficacy of the Company's first-generation Maestro® RF System in the treatment of obesity. Unlike the second-generation Maestro® RC System, which is powered by an internal battery recharged via an external mobile charger and transmit coil worn by the patient for a short time each week, the Maestro® RF System is powered by an external controller and transmit coil which must be worn daily by the patient for the hours prescribed to receive therapy.

The Company today announced updated 30 month data on EWL:

                       ------------------------------
                       Visit              EWL     N  
                       ------------------------------
                       6 Months         -17.9%   271 
                       ------------------------------
                       12 Months        -16.3%   265 
                       ------------------------------
                       18 Months        -17.2%   188 
                       ------------------------------
                       24 Months        -19.2%   164 
                       ------------------------------
                       30 Months        -19.8%   107 
                       ------------------------------
Interim analysis. N at 18, 24 and 30 months are patients who have reached   
those time points and were seen for the scheduled visit.                    

About the ReCharge Pivotal Trial

The ReCharge Clinical Trial is a randomized, double-blind, parallel-group, multicenter pivotal clinical trial in 234 patients at up to 12 sites testing the effectiveness and safety of VBLOC® vagal blocking therapy in EnteroMedics' second generation Maestro® Rechargeable (RC) System. All patients in the study will receive an implanted device and will be randomized in a 2:1 allocation to treatment or control groups. The control group will receive a functional, but non-active device without lead placement on the vagus nerve that will deliver no charge to the vagus nerve during the study period. All patients are expected to participate in a weight management counseling program.

About Maestro® RC System

The Maestro® Rechargeable (RC) System is powered by an internal, rechargeable battery. The battery is recharged via an external mobile charger and transmit coil that the patient uses for a short time each week. The Maestro® RC System delivers VBLOC® vagal blocking therapy via two small electrodes that are laparoscopically implanted and placed in contact with the trunks of the vagus nerve just above the junction between the esophagus and the stomach.

About VBLOC® Therapy

EnteroMedics developed VBLOC® vagal blocking therapy to offer bariatric surgeons and their patients a less invasive alternative to existing surgical weight loss procedures that may present significant risks and alter digestive system anatomy, lifestyle and food choices. VBLOC® Therapy is delivered via the Maestro® System through laparoscopically implanted leads to intermittently block the vagus nerves using high-frequency, low-energy electrical impulses. VBLOC® Therapy is designed to target the multiple digestive functions under control of the vagus nerves and to affect the perception of hunger and fullness.

About EnteroMedics Inc.

EnteroMedics is a development stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity and other gastrointestinal disorders. EnteroMedics' proprietary neuroblocking technology, VBLOC® vagal blocking therapy, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. These electrical impulses are delivered by a neuroregulator, EnteroMedics' Maestro® RC System, which is powered by an integrated rechargeable battery. For more information, visit www.enteromedics.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our lack of regulatory approval for our Maestro® System for the treatment of obesity; our preliminary findings from our EMPOWER™ pivotal trial; our ability to comply with the Nasdaq continued listing requirements; our ability to commercialize our Maestro® System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our Maestro® System; physician adoption of our Maestro® System and VBLOC® vagal blocking therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 7, 2011. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Caution - U.S. Investigational device. Limited within the United States by U.S. Federal law to investigational use.

The implantation procedure and usage of the Maestro® System carry some risks, such as the risk generally associated with laparoscopic procedures and those related to treatment as described in the ReCharge clinical trial informed consent.


Contact:
EnteroMedics Inc.
Greg S. Lea
(651) 789-2860
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->